- Home
- BLFY vs ELDN Comparison
BLFY vs ELDN Comparison
Compare BLFY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFY
- ELDN
- Stock Information
- Founded
- BLFY 1939
- ELDN 2004
- Country
- BLFY United States
- ELDN United States
- Employees
- BLFY N/A
- ELDN N/A
- Industry
- BLFY Commercial Banks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- BLFY Finance
- ELDN Health Care
- Exchange
- BLFY Nasdaq
- ELDN Nasdaq
- Market Cap
- BLFY 191.7M
- ELDN 164.1M
- IPO Year
- BLFY N/A
- ELDN N/A
- Fundamental
- Price
- BLFY $8.92
- ELDN $2.74
- Analyst Decision
- BLFY Hold
- ELDN Strong Buy
- Analyst Count
- BLFY 1
- ELDN 2
- Target Price
- BLFY $10.00
- ELDN $12.50
- AVG Volume (30 Days)
- BLFY 51.8K
- ELDN 1.1M
- Earning Date
- BLFY 10-29-2025
- ELDN 11-11-2025
- Dividend Yield
- BLFY N/A
- ELDN N/A
- EPS Growth
- BLFY N/A
- ELDN N/A
- EPS
- BLFY N/A
- ELDN 0.21
- Revenue
- BLFY $41,939,000.00
- ELDN N/A
- Revenue This Year
- BLFY $19.02
- ELDN N/A
- Revenue Next Year
- BLFY $17.51
- ELDN N/A
- P/E Ratio
- BLFY N/A
- ELDN $12.90
- Revenue Growth
- BLFY 0.22
- ELDN N/A
- 52 Week Low
- BLFY $8.24
- ELDN $2.32
- 52 Week High
- BLFY $11.38
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- BLFY 45.72
- ELDN 51.95
- Support Level
- BLFY $8.63
- ELDN $2.58
- Resistance Level
- BLFY $9.08
- ELDN $2.71
- Average True Range (ATR)
- BLFY 0.25
- ELDN 0.18
- MACD
- BLFY -0.02
- ELDN 0.01
- Stochastic Oscillator
- BLFY 31.14
- ELDN 54.46
About BLFY Blue Foundry Bancorp
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.